Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Liabilities and Shareholders Equity (2016 - 2025)

China Pharma Holdings filings provide 16 years of Liabilities and Shareholders Equity readings, the most recent being $31.0 million for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 108.22% to $31.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $74.8 million, a 27.18% increase, with the full-year FY2025 number at $31.0 million, up 108.22% from a year prior.
  • Liabilities and Shareholders Equity hit $31.0 million in Q4 2025 for China Pharma Holdings, up from $15.8 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $31.0 million in Q4 2025 to a low of $13.5 million in Q3 2024.
  • Median Liabilities and Shareholders Equity over the past 5 years was $16.3 million (2022), compared with a mean of $17.6 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: decreased 21.48% in 2022 and later soared 108.22% in 2025.
  • China Pharma Holdings' Liabilities and Shareholders Equity stood at $22.6 million in 2021, then decreased by 21.48% to $17.8 million in 2022, then dropped by 7.39% to $16.5 million in 2023, then dropped by 9.6% to $14.9 million in 2024, then surged by 108.22% to $31.0 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $31.0 million (Q4 2025), $15.8 million (Q3 2025), and $13.8 million (Q2 2025) per Business Quant data.